Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.790
-0.020 (-1.11%)
At close: Jan 31, 2025, 4:00 PM
1.800
+0.010 (0.55%)
After-hours: Jan 31, 2025, 6:18 PM EST
Esperion Therapeutics Employees
Esperion Therapeutics had 240 employees as of December 31, 2023. The number of employees increased by 41 or 20.60% compared to the previous year.
Employees
240
Change (1Y)
41
Growth (1Y)
20.60%
Revenue / Employee
$1,231,046
Profits / Employee
-$361,546
Market Cap
352.69M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ESPR News
- 6 weeks ago - Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewsWire
- 7 weeks ago - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
- 7 weeks ago - Esperion Announces $210 Million Convertible Debt Financing - GlobeNewsWire
- 7 weeks ago - Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel - GlobeNewsWire
- 7 weeks ago - Will The Long Awaited Breakout For Esperion Therapeutics Hold? - Seeking Alpha
- 2 months ago - Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - GlobeNewsWire
- 2 months ago - Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy - Seeking Alpha
- 3 months ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire